melanoma
Showing NaN - NaN of 113
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)
Recruiting
- Colorectal Carcinoma
- +21 more
- Dual X-ray Absorptiometry
- +2 more
-
Birmingham, Alabama
- +18 more
Jan 30, 2023
Metastatic Solid Tumors, NSCLC, Melanoma Trial in United States (INBRX-105 - PDL1x41BB antibody, Pembrolizumab)
Recruiting
- Metastatic Solid Tumors
- +7 more
- INBRX-105 - PDL1x41BB antibody
- Pembrolizumab
-
Scottsdale, Arizona
- +12 more
Jan 26, 2023
Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab)
Recruiting
- Melanoma
- Pembrolizumab
- +5 more
-
Los Angeles, California
- +39 more
Jan 25, 2023
Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, V937)
Recruiting
- Melanoma
- Pembrolizumab
- +5 more
-
Los Angeles, California
- +28 more
Jan 25, 2023
Melanoma Trial in Worldwide (Pembrolizumab, Quavonlimab, Vibostolimab)
Recruiting
- Melanoma
- Pembrolizumab
- +4 more
-
Los Angeles, California
- +34 more
Jan 25, 2023
Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)
Active, not recruiting
- Melanoma
- +7 more
- Autogene cevumeran
- Atezolizumab
-
Scottsdale, Arizona
- +36 more
Dec 22, 2022
Small Cell Lung Cancer, NSCLC, Squamous, NSCLC, Non-squamous Trial in Worldwide (ladiratuzumab vedotin)
Recruiting
- Small Cell Lung Cancer
- +8 more
- ladiratuzumab vedotin
- pembrolizumab
-
Chandler, Arizona
- +65 more
Dec 19, 2022
Melanoma Trial in Worldwide (Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination)
Recruiting
- Melanoma
- Nivolumab
- Nivolumab + Relatlimab Fixed Dose Combination
-
Birmingham, Alabama
- +185 more
Dec 3, 2022
Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer Trial in United States (RPTR-168)
Terminated
- Head and Neck Squamous Cell Carcinoma
- +2 more
- RPTR-168
-
Scottsdale, Arizona
- +3 more
Dec 2, 2022
Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer Trial in United States (NC318)
Active, not recruiting
- Advanced or Metastatic Solid Tumors
- +8 more
-
Los Angeles, California
- +5 more
Nov 29, 2022
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)
Completed
- Melanoma
- +27 more
- XmAb20717
-
Los Angeles, California
- +16 more
Nov 29, 2022
Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or
Active, not recruiting
- Melanoma
- +8 more
- Pegilodecakin
- +9 more
-
Los Angeles, California
- +9 more
Nov 15, 2022
Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)
Terminated
- Melanoma
- Talimogene Laherparepvec
- +2 more
-
Birmingham, Alabama
- +160 more
Nov 10, 2022
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer Trial in United States (Ulixertinib (BVD-523))
Available
- Pancreatic Cancer
- +20 more
- Ulixertinib (BVD-523)
-
Birmingham, Alabama
- +25 more
Nov 4, 2022
Melanoma Trial in Worldwide (Pembrolizumab, Placebo)
Active, not recruiting
- Melanoma
- Pembrolizumab
- Placebo
-
Tucson, Arizona
- +158 more
Oct 31, 2022
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma Trial in France, United States (TRK-950, Irinotecan, Leucovorin)
Recruiting
- Solid Tumor
- +11 more
- TRK-950
- +14 more
-
Scottsdale, Arizona
- +13 more
Oct 2, 2022
Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal
Recruiting
- Breast Cancer
- +15 more
- ATRC-101
- +2 more
-
Phoenix, Arizona
- +10 more
Sep 28, 2022